"description","label","name","uuid:ID","id","rationale","instanceType"
"The main design for the study","","Study Design 1","971270a3-e363-4f68-bb3f-f53a8ef7a072","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign"
